Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Opposes Switching Asthma Drugs, Oral Contraceptives

This article was originally published in The Tan Sheet

Executive Summary

The firm’s opposition to allowing innovative switches for asthma drugs and oral contraceptives focuses on safety and consumers’ ability to self-select and manage their allergies or reproductive status, but maintains that Plan B One-Step and other emergency contraceptives are appropriate for full OTC status.

Advertisement

Related Content

Asthma Drug Petition Opposes OTC Approach, NSURE Paradigm
Asthma Drug Petition Opposes OTC Approach, NSURE Paradigm
Asthma Drug Petition Opposes OTC Approach, NSURE Paradigm
Sanofi’s Nasacort AQ Rx-To-OTC Switch Under FDA Review
Rescue Medicine Switch Concept Draws Criticism
Birth Control Primed For Switch
Teva Plan B OTC Application Fails Political Test After Clearing FDA Hurdle
Asthma Treatment OTC Switches Would Face Tough Barriers
Teva's Plan B One-Step OTC Application Puts FDA On The Spot
Advocates For Switching Birth Control Pill Face Social, Risk Obstacles

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS105796

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel